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operatively obtained, segmented, and reconstructed in 3D. During the procedure, the 3D
CT images, EAM data and real-time catheter position were imported into a custom work-
station. The electrophysiologist was blinded to these images, but the accuracy of the reg-
istration of these datasets was assessed prospectively by a second operator.
Results: Simulations were used to investigate 6 registration strategies employing a com-
bination of the descending Ao, PVs, and LA. The optimal strategy involved registering
points from both the Ao and LA; this resulted in an average distance from EA point to LA
image surface of 1.82 mm. To validate the in vivo registration, the catheter was localized
to the PV ostia on the registered CT image (confirmed by contrast injections under fluo-
roscopy). Also, after proper registration, the ridge between the LSPV and the LA append-
age was co-localized in both the CT and EAM datasets.
Conclusions: This study supports the feasibility of the general hypothesis that registra-
tion of pre-acquired cardiac images with real-time EA mapping can guide catheter move-
ment in the LA in a reliable and clinically-relevant manner.
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1053-209 Amiodarone in Survivors of Life-Threatening Ventricular 
Arrhythmias: Does It Improve Outcome? Results of the 
Leiden Out of Hospital Cardiac Arrest Trial (LOHCAT)
Philippine Kiès, Jeroen J. Bax, Alida E. Borger van der Burg, Eric Boersma, Marianne 
Bootsma, Lieselot van Erven, Ernst E. van der Wall, Martin J. Schalij, Leiden University 
Medical Center, Leiden, The Netherlands, Erasmus Medical Center, Rotterdam, The 
Netherlands
Introduction: Survivors of life-threatening ventricular arrhythmias (VA) are at increased
risk of death and recurrences. One-fourth of patients is discharged with amiodarone as
primary therapy or in addition to an implantable cardioverter defibrillator (ICD). The aim
of this study was to establish the effect of amiodarone on death and on the composite
endpoint of death and recurrences.
Methods: A total number of 417 consecutive survivors of life-threatening VA (328 male,
age 59±13 years) were included in a standardized screening and evaluation protocol to
determine the underlying pathology and optimise patient-tailored therapy. Multivariable
Cox’ regression analysis was performed to evaluate the relation between amiodarone
and survival and the composite endpoint of survival and recurrences. We adjusted for left
ventricular (LV) ejection fraction, LV dimensions, age, ischemic heart disease, inducibility
at electrophysiological test, revascularization, ICD and several other drugs.
Results: The majority of patients had ischemic heart disease (296, 71%). During follow-
up (32±25 months), 45 (10%) patients died (31 heart failure, 4 sudden death, 10 non-car-
diac). Amiodarone was administered in 110 (26%) patients, of whom 22 (20%) died, as
compared to 23 deaths (7.5%) in the patients without amiodarone (crude hazard ratio
(HR) 3.4, 95% CI 1.9-6, P<0.001). After adjustment for the previously mentioned vari-
ables, amiodarone still was associated with an increased risk on long-term mortality
(adjusted HR 3.7, 95% CI 1.1-12.6, P=0.03). Similar results were found for the composite
endpoint of death and/ or recurrences (crude HR 2.6, 95% CI 1.9-3.6, P<0.001 and
adjusted HR 1.9, 95% CI 1.1-3.2, P=0.03). Furthermore, this relation was found in
patients with and without ischemic heart disease.
Conclusion: Amiodarone may be associated with an increased risk of death (and recur-
rences), both in patients with and without ischemic heart disease. In view of these data, it
can be questioned whether amiodarone improves long-term outcome in survivors of life-
threatening VA.
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Background The incidence and prognosis of malignant ventricular arrhythmias (VA)
among patients with non-ST elevation acute coronary syndromes (NSTE-ACS) in clinical
practice is unknown. Most available data come from selected randomized clinical trials,
suggesting increased in-hospital and post-discharge mortality. The aim of this study was
to examine the incidence, predictors and outcomes of VA (ventricular tachycardia, ven-
tricular fibrillation and cardiac arrest) among patients with NSTE-ACS.
Methods We evaluated 17,545 patients with NSTE-ACS (non-ST elevation myocardial
infarction and unstable angina) from the Global Registry of Acute Coronary Events
(GRACE), and compared those who developed VA and increased hospital mortality to
those who did not. Adjustment for other risk factors related to increased mortality was
performed. Independent predictors of in-hospital VA were analyzed through multivariate
logistic regression modeling.
Results Presence of VA remained statistically significant after adjustment for demo-
graphics, treatment and clinical factors in a multivariate logistic model.
Conclusions In an unselected NSTE-ACS population from the observational GRACE
registry, the occurrence of in-hospital ventricular arrhythmic events was independently
associated with substantially higher in-hospital mortality. Prompt identification of predic-
tors of arrhythmic events and implementation of effective therapies are needed to
improve the survival of those patients. 
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Background: Depression predicts mortality in patients with coronary artery disease
(CAD), but whether this is due to ventricular arrhythmia (VT/VF) is unknown.
Methods: To address this question, we prospectively examined the relationship between
baseline symptoms of depression and risk of VT/VF resulting in ICD discharge in the
Triggers of Ventricular Arrhythmias (TOVA) study. Symptoms were assessed by the Cen-
ter for Epidemiologic Studies-Depression (CES-D) scale. Scores of 16 to 27 and >27 rep-
resented mild and moderate to severe depression, respectively. Proportional hazards
models tested for associations among 1) all patients and 2) CAD patients, with adjust-
ment for prior shocks, age, sex, smoking, alcohol, hypertension, angina and CHF class,
and LVEF.
Results: Among 625 patients followed a median 186 days, 45 received ICD shocks for
VT/VF. Depression (CES-D score>16) was present in 111 (17.8%). Depression severity
was significantly related to VT/VF among all patients and among those in the CAD sub-
group (table). As compared to those without depression (CES-D score<16), the risk of
VT/VF was significantly elevated among patients with moderate to severe depression
(CES-D score>27), particularly among those with CAD who had a 7-fold increased risk of
VT/VF.
Conclusion: Depression severity predicts shocks for VT/VF among ICD patients. The
elevated risk of VT/VF may explain, at least in part, the higher cardiovascular mortality
observed in depressed patients, particularly those with CAD. 
1053-212 Temporal Patterns of Ventricular Tachyarrhythmia 
Recurrences Follow a Weibull Distribution
Mark Wood, Amy Xia, Xiaohong Zhou, Vasant Padmanabhan, Kenneth Ellenbogen, 
Medical College of Virginia, Richmond, VA, Medtronic, Inc., Minneapolis, MN
BACKGROUND: Understanding the temporal pattern of arrhythmias is essential to prop-
erly assess the response to antiarrhythmic therapies. Commonly used statistical mea-
sures usually assume a uniformly random pattern of tachyarrhythmias (VT) over time.
Table 1: Outcomes in NSTEMI/Unstable Angina Patients with Ventricular Arrhythmias
VT/VF CA VT/VF/
CA
No VT/VF/
CA
P value
Number of patients (% of 
total)
487 (2.8) 618 (3.6) 869 (5) 16,582 (95)
Death (%) 192 (40) 499 (81) 527 (61) 243 (2) <0.0001
OR 95% CI
In-hospital death (GRACE risk model) 75.0 59.1-94.5
VT, ventricular tachycardia; VF, ventricular fibrillation; CA, cardiac arrest
Table 2: Predictors of Ventricular Arrhythmia (Logistic Model)
OR 95% CI
In-hospital congestive heart failure 3.4 2.80-4.14
ST-segment deviation 1.4 1.16-1.61
Killip (per 1-class increase) 1.3 1.12-1.43
Pulse (per 30-bpm increase) 1.3 1.13-1.38
Initial serum creatinine (per 1-unit increase) 1.2 1.11-1.25
Initial cardiac enzymes 1.2 1.03-1.44
Age (per 10-year increase) 1.1 1.04-1.19
History of hypertension 0.8 0.69-0.96
Male 0.8 0.66-0.94
History of percutaneous coronary intervention 0.6 0.50-0.83
Hazard Ratios (95% CI) for VT/VF, Multivariable Analyses
All Patients
(n=625)
Patients with CAD
(n=465)
CES-D > 16 and < 27 1.58 (0.69 - 3.65) 1.96 (0.80 - 4.85)
CES-D > 27 4.06 (1.32 - 12.46) 7.55 (2.15 - 26.56)
P for trend 0.017 0.002
